Danaher Co. (NYSE:DHR) Shares Sold by Aspiriant LLC

Aspiriant LLC lowered its position in Danaher Co. (NYSE:DHR) by 0.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,526 shares of the conglomerate’s stock after selling 62 shares during the period. Aspiriant LLC’s holdings in Danaher were worth $1,630,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Cary Street Partners Investment Advisory LLC lifted its stake in Danaher by 20.2% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after buying an additional 1,533 shares in the last quarter. First Citizens Bank & Trust Co. lifted its stake in Danaher by 0.6% in the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after buying an additional 149 shares in the last quarter. Cercano Management LLC lifted its stake in Danaher by 11.4% in the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after buying an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares in the last quarter. Finally, Caden Capital Partners LP lifted its stake in Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after buying an additional 15,313 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price target on the stock. Barclays increased their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 24th. Bank of America increased their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Finally, Citigroup increased their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $269.29.

Danaher Stock Down 0.1 %

Shares of NYSE DHR opened at $253.77 on Thursday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $269.11. The company has a market cap of $187.96 billion, a P/E ratio of 43.01, a P/E/G ratio of 3.89 and a beta of 0.85. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average price of $255.07 and a 200 day moving average price of $246.14.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the prior year, the firm earned $2.36 EPS. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity

In other news, SVP Brian W. Ellis sold 4,000 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock worth $37,536,717 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.